In a 12-week phase 2 trial of 24 adults with type 1 diabetes and BMI >30, weekly tirzepatide reduced weight by 10.3 kg vs 0.7 kg with placebo (difference -8.7 kg, 8.8%); 22 completed. HbA1c fell 0.4% and insulin dose fell; no significant adverse events.
RCTn = 24
Snaith et al. Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial